7.78
0.28 (3.73%)
| Previous Close | 7.50 |
| Volume | 389,805 |
| Price / Earnings (Forward) | 370.37 |
| Price / Sales | 5.16 |
| Price / Book | 5.37 |
| 52 Weeks Range |
| Profit Margin | -67.28% |
| Operating Margin (TTM) | -78.39% |
| Diluted EPS (TTM) | -1.17 |
| Quarterly Revenue Growth (YOY) | -27.00% |
| Total Debt/Equity (MRQ) | 71.85% |
| Current Ratio (MRQ) | 5.96 |
| Operating Cash Flow (TTM) | 6.54 M |
| Levered Free Cash Flow (TTM) | 9.81 M |
| Return on Assets (TTM) | -4.64% |
| Return on Equity (TTM) | -44.32% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Maravai LifeSciences Holdings, | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.17 |
|
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.21% |
| % Held by Institutions | 89.67% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |